Under the terms of the deal, BMS will acquire all outstanding shares of
The deal includes Karuna's lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia.
KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain.
Currently under review by the
KarXT's novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy…”
"Schizophrenia and Alzheimer's disease psychosis affect millions of people worldwide, with limited to no treatment options. KarXT's novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile," said
"KarXT also has the potential to deliver meaningful benefits to patients…as a first treatment for Alzheimer's disease psychosis," Hirawat added.
Registrational clinical trials are currently underway evaluating KarXT for the treatment of Alzheimer's disease psychosis, with data expected in 2026. There are an estimated 6 million people living with Alzheimer's in the US, and no currently approved treatments for AD psychosis.
Additional, the company said it "sees potential from Karuna's early-stage and pre-clinical pipeline."
"This transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need," said
The transaction is expected to close in the first half of 2024, subject to customary closing conditions.
The post BMS strikes
© Russell Publishing Limited, 2023. All Rights Reserved., source